PPARG and Parkinson disease: As demonstrated in vitro the PPARγ agonist rosiglitazone has anti-oxidant effects that appear not to require PPARγ activation, and which may contribute to the previously documented neuroprotective effects of rosiglitazone in in vivo models of PD (Schintu et al., 2009; Carta et al., 2011).